XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue:    
Total revenue $ 114,473 $ 96,844
Cost of revenue:    
Intangible asset amortization - cost of revenue 2,585 2,915
Total cost of revenue 34,965 34,376
Gross profit 79,508 62,468
Operating expenses:    
Research and development 17,720 15,965
Selling and marketing 24,454 23,782
General and administrative 33,808 26,210
Impairment of long-lived assets 0 429
Total operating expenses 76,604 67,124
Income (loss) from operations 2,904 (4,656)
Other income, net 4,524 2,748
Income (loss) before income taxes 7,428 (1,908)
Income tax provision (benefit) 381 (44)
Net income (loss) $ 7,047 $ (1,864)
Earnings (loss) per share:    
Basic (in USD per share) $ 0.09 $ (0.02)
Diluted (in USD per share) $ 0.09 $ (0.02)
Shares used to compute earnings (loss) per common share:    
Basic (in shares) 78,028,254 74,759,789
Diluted (in shares) 80,056,024 74,759,789
Testing revenue    
Revenue:    
Total revenue $ 107,309 $ 90,303
Cost of revenue:    
Cost of revenue 28,260 25,979
Product revenue    
Revenue:    
Total revenue 3,580 3,537
Cost of revenue:    
Cost of revenue 1,422 2,644
Biopharmaceutical and other revenue    
Revenue:    
Total revenue 3,584 3,004
Cost of revenue:    
Cost of revenue 2,698 2,838
Intangible Asset Amortization    
Operating expenses:    
Intangible asset amortization - operating expenses $ 622 $ 738